BGN and cancer: Biglycan holds great potential as biomarker as deregulated levels of soluble biglycan are detected in a variety of inflammatory and chronic disease, such lupus nephritis (144), diabetes (162, 163), fibrosis (164), renal diseases (159), and cancer (165), biglycan holds great potential as biomarker.